Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
Why Summit Therapeutics Stock Slipped Today
Summit Therapeutics (SMMT -2.25%) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit more or less kept pace with the S&P 500 (^GSPC -1.12%), managing to dip by a relatively modest 2.25% in price.
Summit Therapeutics upgraded ahead of lung cancer trial data readout
Summit Therapeutics PLC (NASDAQ:SMMT) has been upgraded to a ‘Buy' rating by Citi analysts who are optimistic about the company's HARMONi-2 trial of ivonescimab in non-small cell lung cancer. Citi also boosted its price target to $35.
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
On Friday, Cantor Fitzgerald initiated coverage on Summit Therapeutics Inc. SMMT, citing shares as 67% undervalued.
Is Summit Therapeutics a Millionaire Maker?
Multiple paths to immense wealth exist. A few lucky people win the lottery.
This Unstoppable Biotech Stock Just Became an Even Better Buy
Last year, Summit Therapeutics (SMMT -1.24%) was one of the stars of the biotech industry. The company's shares soared following a significant clinical win.
Why Summit Therapeutics Stock Was Winning This Week
A very bullish analyst move was the news generally responsible for Summit Therapeutics' (SMMT -3.62%) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before market open, as according to data compiled by S&P Global Market Intelligence Summit's share price had risen by almost 8% week to date at that point.
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
Summit Therapeutics (SMMT 7.62%) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch. But things have slowed of late and since the start of 2025, the stock's returns have been flat.
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Is Summit Therapeutics a Millionaire Maker?
Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (SMMT -2.71%). The drugmaker's shares are up by nearly 540%, thanks to excellent clinical progress for its leading pipeline candidate, ivonescimab, a cancer treatment in development.
2 Stocks That Could Soar Again in 2025
Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (VKTX 3.50%) and Summit Therapeutics (SMMT -2.71%).
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?
It can be exciting to buy a stock that has been red hot and to jump on the bandwagon -- but doing so can come with significant risks. At some point, there's a danger that the stock's rally could dissipate, and at that point, a sell-off may ensue.
Why Summit Therapeutics Stock Is Jumping Today
Shares of Summit Therapeutics (SMMT 15.40%) had jumped 14.3% at 11:31 a.m. ET on Tuesday.
